X4 Pharmaceuticals, Inc.
XFOR
$3.58
$0.082.18%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 11.61% | -783.12% | -111.48% | -467.43% | -678.36% |
| Total Depreciation and Amortization | 21.52% | -15.37% | 60.43% | 126.84% | 224.88% |
| Total Amortization of Deferred Charges | 7.81% | 5.20% | 1.05% | -4.87% | -12.61% |
| Total Other Non-Cash Items | 741.60% | 105.41% | 93.88% | 96.92% | 98.82% |
| Change in Net Operating Assets | 21.43% | 36.62% | -196.30% | -77.83% | -702.35% |
| Cash from Operations | 23.39% | 15.34% | 34.59% | 17.96% | 2.80% |
| Capital Expenditure | -- | -- | -- | 87.19% | 43.64% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -100.00% | -100.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 244.77% | 185.90% | 121.64% | 49.04% | 80.86% |
| Cash from Investing | 240.56% | -55.84% | -87.83% | -124.47% | -105.61% |
| Total Debt Issued | -- | -- | -- | -100.00% | -100.00% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 3,942.21% | 81,066.67% | 81,065.99% | 36,099.61% | 2,152.34% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 3,942.21% | 1,075.86% | 1,075.85% | 357.50% | -86.09% |
| Foreign Exchange rate Adjustments | -117.42% | 584.00% | 236.54% | -115.81% | 700.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 244.24% | 972.24% | 468.67% | 19.30% | -1,124.42% |